Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

Blood (2024) 143 (11): 983–995.

https://doi.org/10.1182/blood.2023021564

Published: 2024

Includes: Supplemental data

Journal Articles

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Blood (2023) 142 (Supplement 1): 170.

https://doi.org/10.1182/blood-2023-178030

Published: 2023

Journal Articles

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Blood (2023) 142 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2023-188896

Published: 2023

Journal Articles

Spplaash Study: A Randomized Study to Evaluate the Incidence of Postdural Puncture Headache with the Use of Atraumatic Needles in Hematology

Yann Guillermin, Stéphane Morisset, Ugo Thévenet, Emmanuelle Nicolas-Virelizier, Anne-Sophie Michallet, Jerome Cornillon, Manon Sapet, Valentin Daguerre, Emmanuel Beillard, Denis Guyotat, Elisabeth Daguenet, Ludovic Fouillet

Blood (2023) 142 (Supplement 1): 129.

https://doi.org/10.1182/blood-2023-180601

Published: 2023

Journal Articles

Long-Term Outcome of Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation (ASCT) - Impact of Therapeutic Strategy Following ASCT

Emilie Martin, Stéphane Morisset, Mohamad Sobh, Alfred Quillon, Hélène Boyer, Philippe Rey, Emmanuelle Nicolas-Virelizier, Amine Belhabri, Yann Guillermin, Laure Lebras, Valérie Mialou, Jean Paul Bourgeot, Melinda Teyssier, Anne-Sophie Michallet, Mauricette Michallet

Blood (2023) 142 (Supplement 1): 6682.

https://doi.org/10.1182/blood-2023-182700

Published: 2023

Journal Articles

Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring

Michael Philippe, Jerome Guitton, Bertrand Favier, Clemence Santana, Emmanuelle Nicolas-Virelizier, Yann Guillermin, Anne-Sophie Michallet, Mauricette Michallet, Amine Belhabri

Blood (2022) 140 (Supplement 1): 6179–6180.

https://doi.org/10.1182/blood-2022-168327

Published: 2022

Journal Articles

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Blood (2022) 140 (Supplement 1): 2302–2305.

https://doi.org/10.1182/blood-2022-165217

Published: 2022

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Blood (2022) 139 (15): 2338–2346.

https://doi.org/10.1182/blood.2021013526

Published: 2022

Includes: Supplemental data

Journal Articles

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Blood (2021) 138 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2021-148678

Published: 2021

Journal Articles

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Blood (2021) 138 (Supplement 1): 1387.

https://doi.org/10.1182/blood-2021-150478

Published: 2021

Journal Articles

Final Analysis of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA) Using Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Patients over 60 Years with Advanced-Stage Classical Hodgkin Lymphoma

Blood (2021) 138 (Supplement 1): 1370.

https://doi.org/10.1182/blood-2021-152346

Published: 2021

Journal Articles

Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

Blood (2021) 138 (Supplement 1): 232.

https://doi.org/10.1182/blood-2021-147863

Published: 2021

Journal Articles

Study of Treatment Complications in Oncology / Hematology Patients: Protocol for a Prospective and Interventional Cohort Study from the Pasca Program

Mauricette Michallet, MD PhD, Romain Buono, PharmD, Mohamad Sobh, PharmD, Solene Poirey, Emmanuelle Nicolas-Virelizier, MD, Souad Assaad, MD, Amine Belhabri, MD, Laure Lebras, MD, Yann Guillermin, MD, Philippe Rey, MD, Aude Flechon, MD PhD, Helen Boyle, MD, Franck E Nicolini, MDPhD, Audrey Couillet, Gisele Chvetzoff, Jean-Yves Blay, MD PhD, Beatrice Fervers, Anne-Sophie Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-142355

Published: 2020

Journal Articles

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Amine Belhabri, MD, Liliana Vila, MD, Mael Heiblig, Stephane Morisset, BioStat, Emmanuelle Nicolas-Virelizier, MD, Clémence Santana, MD, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Anne-Sophie Michallet, MD PhD, Philippe Rey, MD, Yann Guillermin, MD, Souad Assad, MD, Laure Lebras, MD, Mauricette Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142956

Published: 2020

Journal Articles

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-139224

Published: 2020

Journal Articles

Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma

Blood (2020) 136 (Supplement 1): 43–45.

https://doi.org/10.1182/blood-2020-138789

Published: 2020

Journal Articles

Retrospective Evaluation of Rituximab, Methotrexate, Procabazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-139946

Published: 2020

Journal Articles

PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136056

Published: 2020

Journal Articles

Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma

Guillaume Manson, Pauline Brice, Charles Herbaux, MD MSc, Maria Silva, Krimo Bouabdallah, MD, Bénédicte Deau-Fisher, MD, Juliette Bouteloup, MD, Jean Marc Schiano de Collela, MD, Emmanuelle Nicolas-Virelizier, Marie Maerevoet, MD, Herve Ghesquieres, MD PhD, Aspasia Stamatoulas Bastard, Chloe Antier, Florence Poizeau, Laurent Dercle, MD, Roch Houot, MD PhD

Blood (2019) 134 (Supplement_1): 1549.

https://doi.org/10.1182/blood-2019-122171

Published: 2019

NARROW

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Spplaash Study: A Randomized Study to Evaluate the Incidence of Postdural Puncture Headache with the Use of Atraumatic Needles in Hematology

Long-Term Outcome of Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation (ASCT) - Impact of Therapeutic Strategy Following ASCT

Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Final Analysis of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA) Using Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Patients over 60 Years with Advanced-Stage Classical Hodgkin Lymphoma

Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

Study of Treatment Complications in Oncology / Hematology Patients: Protocol for a Prospective and Interventional Cohort Study from the Pasca Program

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma

Retrospective Evaluation of Rituximab, Methotrexate, Procabazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma

PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study

Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only